Home
Storia in 3 fonti
Novo Nordisk shares slump after drug failure in Alzheimer’s trial
Outcome is blow to one of Europe’s largest listed companies
- ·
cnbc.com
Novo Nordisk shares plunge 10% after Alzheimer's drug trial fails to hit key target
Shares of Novo Nordisk plunged after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer's disease failed to meet its main goal.
- ·
ft.com
Bayer soars on promising trial results for stroke prevention drug
Findings are respite for German conglomerate facing sliding sales of blockbuster drugs and US legal challenges
- ·
Novo Nordisk shares slump after drug failure in Alzheimer’s trial
Outcome is blow to one of Europe’s largest listed companies
- ·
forbes.com
Novo Nordisk Shares Plummet After Its Alzheimer’s Drug Trial Fails
The company said the weight loss and diabetes treatment drug failed to show any significant reduction in the progression of Alzheimer's disease in patients.
- ·
New Novo drug delivers significant weight-loss benefits in diabetes trial
Amycretin also improved participants’ blood sugar levels in positive sign for Danish company’s treatment pipeline